270 related articles for article (PubMed ID: 7512437)
1. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer.
Piver MS; Recio FO; Baker TR; Driscoll D
Cancer; 1994 Mar; 73(6):1693-8. PubMed ID: 7512437
[TBL] [Abstract][Full Text] [Related]
2. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma.
Piver MS; Lele SB; Marchetti DL; Baker TR; Emrich LJ; Hartman AB
J Clin Oncol; 1988 Nov; 6(11):1679-84. PubMed ID: 3183700
[TBL] [Abstract][Full Text] [Related]
3. Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer.
Recio FO; Piver MS; Hempling RE; Driscoll DL
Gynecol Oncol; 1998 Mar; 68(3):267-73. PubMed ID: 9570979
[TBL] [Abstract][Full Text] [Related]
4. Survival with intraperitoneal cisplatin in advanced ovarian cancer after second-look laparotomy.
de Gramont A; Demuynck B; Louvet C; Gonzalez-Canali G; Varette C; Pigné A; Marpeau L; Herbulot P; Lagadec B; Cady J
Am J Clin Oncol; 1992 Feb; 15(1):7-11. PubMed ID: 1550083
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
[TBL] [Abstract][Full Text] [Related]
6. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP
Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy.
Howell SB; Zimm S; Markman M; Abramson IS; Cleary S; Lucas WE; Weiss RJ
J Clin Oncol; 1987 Oct; 5(10):1607-12. PubMed ID: 2443622
[TBL] [Abstract][Full Text] [Related]
8. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal cisplatin chemotherapy in ovarian carcinoma patients who are clinically in complete remission.
Menczer J; Ben-Baruch G; Rizel S; Brenner H
Gynecol Oncol; 1992 Aug; 46(2):222-5. PubMed ID: 1500025
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission.
Tournigand C; Louvet C; Molitor JL; Fritel X; Dehni N; Sezeur A; Pigné A; Cady J; Milliez J; de Gramont A
Gynecol Oncol; 2003 Nov; 91(2):341-5. PubMed ID: 14599864
[TBL] [Abstract][Full Text] [Related]
12. Ip chemotherapy employing a regimen of cisplatin, cytarabine, and bleomycin.
Markman M; Cleary S; Lucas W; Weiss R; Howell SB
Cancer Treat Rep; 1986 Jun; 70(6):755-60. PubMed ID: 2425962
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer.
Yen MS; Juang CM; Lai CR; Chao GC; Ng HT; Yuan CC
Int J Gynaecol Obstet; 2001 Jan; 72(1):55-60. PubMed ID: 11146078
[TBL] [Abstract][Full Text] [Related]
14. First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer.
Zylberberg B; Dormont D; Madelenat P; Daraï E
Eur J Gynaecol Oncol; 2004; 25(3):327-32. PubMed ID: 15171311
[TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal cytosine arabinoside administered in sequence with systemic cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
Campora E; Bruzzone M; Chiara S; Alama A; Iskra L; Carnino F; Parodi S; Foglia G; Ragni N; Rosso R
Gynecol Oncol; 1990 Apr; 37(1):39-43. PubMed ID: 2323610
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.
Reichman B; Markman M; Hakes T; Hoskins W; Rubin S; Jones W; Almadrones L; Ochoa M; Chapman D; Saigo P
J Clin Oncol; 1989 Sep; 7(9):1327-32. PubMed ID: 2671288
[TBL] [Abstract][Full Text] [Related]
18. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal chemotherapy with cisplatin and etoposide in ovarian carcinoma patients who are clinically in complete remission.
Menczer J; Ben-Baruch G; Rizel S; Brenner H
Eur J Gynaecol Oncol; 1995; 16(1):12-7. PubMed ID: 7744111
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
Gao KF; Liu FY; Chen FJ; Feng YL
Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
